Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Gastric or GEJ Adenocarcinoma
NCT07449780Phase 3Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07449780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449780.